If lirentelimab reduces eosinophils in diseases characterised by eosinophil accumulation, why doesn’t it work?
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
The company’s Enigma study in an orphan digestive tract disease points a way to approval, notwithstanding the company’s statistical analysis method.
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…